Featured Sponsor Video

Advertisement

3 Reasons for XOLAIR® (omalizumab): The CSU Story

 

 

Please see Full Prescribing Information, including Boxed WARNING and Medication Guide, at https://qr.qrhub.ly/XXOLPI

This video is intended for US healthcare professionals only.

This video is sponsored by Genentech USA, Inc. and Novartis Pharmaceuticals Company.

 

 

Take a closer look at what XOLAIR offers as a treatment for CSU. Learn more about XOLAIR at https://www.xolairhcp.com/chronic-spontaneous-urticaria.html

 

 

INDICATION

XOLAIR® (omalizumab) is indicated for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment.

Limitations of Use: XOLAIR is not indicated for treatment of other forms of urticaria.

Advertisement